Table 1.

Risk factors of cerebral venous thrombosis.^{[5,12,14–36]}

Prothrombotic states	Infection (12%)[5,14,26–28]
Hereditary conditions (34–41%)[5,12,14–18]	1. ENT and face infection (8.2–11%) 2. Systemic infectious diseases (4.3%) 3. Meningitis (2.1%)
1. Prothrombin G20210A mutation (9–21%) 2. Factor V Leiden mutation (9–13%) 3. MTHFR mutation (4.5%) 4. Antithrombin deficiency (3%) 5. Protein C deficiency (2–5%) 6. Protein S deficiency (2–3%)
	Mechanical causes[5,12,27–30]
	1. Lumbar puncture (1.9%) 2. Head trauma (1.1%) 3. Jugular vein catheterization (1%) 4. Neurosurgical procedures (0.6%) 5. Trauma to cerebral sinuses
Acquired conditions (15.7%)[5,12,14,17–19]
1. Pregnancy and puerperium (11–59%) 2. Antiphospholipid antibody syndrome (6–17%) 3. Nephrotic syndrome (0.6–1%) 4. Hyperhomocysteinemia
	Malignancy (7.4%)[30–32]
	1. CNS tumors 2. Systemic malignancies 3. Myeloproliferative neoplasms
Haematology[5,12,14,20]	Drugs[5,12,14,30,33,34]
1. Severe anemia (9–27%) 2. Polycythaemia 3. Thrombotic thrombocytopenic purpura 4. Heparin-induced thrombocytopenia	1. Oral contraceptives (54–71%) 2. Hormone replacement therapy (4.3%) 3. Cytotoxic drugs (0.8%) 4. Intravenous immunoglobulin 5. Steroids
Autoimmune and Inflammatory diseases[5,14,21–25]	Miscellaneous[12,14,30,35,36]
1. Inflammatory bowel disease (1.6–3%) 2. Systemic lupus erythematosus (1%) 3. Behçet’s disease (1%) 4. Sarcoidosis (<1%) 5. Thyrotoxicosis (1.7%) 6. COVID-19 vaccine (<1%)	1. Obesity (23%) 2. Dehydration (1.9%) 3. Dural A-V fistulae (1.6%) 4. Arteriovenous malformations (0.2%) 5. No identifiable reasons (12.5%)

Methylenetetrahydrofolate Reductase (MTHFR); ENT- Ear, Nose, and Throat.

Percentage (%) denotes the prevalence of the risk factors. The data expressed in the table were obtained from original research works and review literature.^{[5,12,14–36]}